BHB810 / BigHat Biosci - LARVOL DELTA

BHB810: A novel site-specific CDH17-directed VHH-Fc ADC for gastric cancer (AACR 2026) - "BHB810 is a novel, potentially best-in-class CDH17-directed ADC for the treatment of advanced gastric and other GI malignancies. The molecule was engineered on BigHat Biosciences's AI/ML-powered antibody design platform to maximise ADC internalization and potency against cells that express CDH17. First-in-human studies are planned for 2026, prioritizing patients with gastric cancer."

ADC • First-in-human • Gastric Cancer • Oncology • Solid Tumor • CDH17 • CLDN18 • HER-2